Clinical Trials Browser

Ovarian Neoplasms × liposomal doxorubicin × 1 year × Clear all

NCT04092270 2026-04-17

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Phase 1 Active not recruiting

54 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT07213804 2026-04-17

FRAmework-01

Phase 3 Recruiting

1,080 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07214779 2026-04-16

MAESTRA 2

Phase 3 Recruiting

466 enrolled

Gynecologic

Ovarian Neoplasms

NCT02839707 2026-04-13

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06787612 2026-04-08

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Phase 2 Recruiting

220 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05610735 2026-03-19

Combination Therapy for Recurrent Ovarian Cancer

Phase 1/2 Recruiting

72 enrolled

Gynecologic

Ovarian Neoplasms

NCT07286266 2026-03-19

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Phase 3 Not yet recruiting

450 enrolled

Gynecologic

Ovarian Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

186 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled

Gynecologic

Ovarian Neoplasms

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Phase 1 Active not recruiting

40 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Phase 2/3 Active not recruiting

582 enrolled 21 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05467670 2026-03-04

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Phase 2 Active not recruiting

16 enrolled

Gynecologic

Ovarian Neoplasms

NCT06619236 2026-03-03

RAINFOL-02

Phase 3 Active not recruiting

530 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06161025 2026-01-12

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

30 enrolled

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1 Completed

86 enrolled 17 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02364713 2025-12-11

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Phase 2 Terminated

17 enrolled 14 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05613088 2025-10-20

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

106 enrolled 23 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

600 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

198 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06292286 2025-06-11

SCENIC

Phase NA Recruiting

18 enrolled

Gynecologic

Ovarian Neoplasms

NCT05567601 2025-06-05

Doxil/Caelyx BE Study

Phase 1 Completed

36 enrolled

BreastGynecologicPlasma cellSarcoma

AIDS-related Kaposi sarcoma, Breast Neoplasms, Multiple Myeloma, Ovarian Neoplasms